gimli

NEPHROPLUS stock AI analysis

NEPHROPLUS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

NEPHROCARE HEALTH SERV L is a small-cap stock in Healthcare. This Gimli page shows the latest available NEPHROPLUS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive NEPHROPLUS stock page

Price

₹628.80

1W return

-1.89%

1M return

-14.30%

3M return

+9.71%

6M return

+27.09%

1Y return

n/a

Market cap

₹6,309.42 cr

82.11

5.65

ROE

+9.04%

ROCE

+15.48%

RSI

39.80

Turnover

₹4.79 cr

Why it can matter in screens

Momentum: NEPHROPLUS is below 50DMA, below 200DMA; RSI is 39.80.
Returns: 1D -1.09%, 1W -1.89%, 1M -14.30%, 3M +9.71%, 1Y n/a.
Trend levels: 52W high ₹751.30, 52W low ₹449.15, off high -16.31%.
Liquidity: latest turnover is ₹4.79 cr; volume vs 20D is +0.39%.
Valuation/profitability: PE 82.11, PB 5.65, ROE +9.04%, ROCE +15.48%.
Growth: 3Y sales CAGR +34.06%, 3Y profit CAGR n/a.

Quick Answers

What is the latest NEPHROPLUS stock price?

The latest stored price for NEPHROPLUS is Rs 628.80 as of 2026-07-20.

Is NEPHROPLUS above its 50DMA and 200DMA?

NEPHROPLUS is below 50DMA, below 200DMA. The latest 50DMA is 655.23 and the latest 200DMA is n/a.

What are NEPHROPLUS PE, ROE and ROCE?

NEPHROPLUS has PE 82.11, ROE +9.04%, and ROCE +15.48% in Gimli's latest available snapshot.

How has NEPHROPLUS performed recently?

NEPHROPLUS has returned -14.30% over 1 month, +9.71% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	265.62 cr	62.24 cr	30.37 cr	3.03
2025-12-31	259.73 cr	64.18 cr	32.24 cr	3.43
2025-09-30	249.61 cr	67.81 cr	-9.47 cr	-1.12
2025-03-31	219.19 cr	55.41 cr	24.87 cr	2.48
2024-12-31	197.26 cr	49.46 cr	20.11 cr	2.00

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	998.85 cr	248.38 cr	76.84 cr	8.48
2025-03-31	755.81 cr	180.74 cr	67.10 cr	6.69
2024-03-31	539.55 cr	107.05 cr	35.13 cr	3.50
2023-03-31	414.52 cr	52.87 cr	-11.79 cr	-1.17
2022-03-31	320.46 cr	21.43 cr	-21.98 cr	-132.53

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	1,470.87 cr	123.89 cr	79.71 cr	1,116.49 cr
2025-03-31	996.46 cr	125.82 cr	257.78 cr	584.11 cr
2024-03-31	806.02 cr	61.15 cr	267.84 cr	413.71 cr
2023-03-31	666.23 cr	13.19 cr	213.73 cr	388.63 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	232.58 cr	113.22 cr	n/a
2025-03-31	135.35 cr	34.55 cr	n/a
2024-03-31	72.28 cr	-7.72 cr	n/a
2023-03-31	11.27 cr	-62.47 cr	n/a
2022-03-31	n/a	n/a	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-03-31	+63.85%	+9.94%	+8.65%	+3.17%	+17.56%	+0.00%
2025-12-31	+63.85%	+9.30%	+8.10%	+3.10%	+18.74%	+0.00%
2025-12-16	+63.85%	+3.59%	+8.68%	+3.44%	+23.88%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	469,405.90 cr	40.823336	+14.71%	+15.52%
DIVISLAB	DIVI S LABORATORIES LTD	194,269.92 cr	75.650281	+16.19%	+8.71%
TORNTPHARM	TORRENT PHARMACEUTICALS L	169,405.46 cr	78.319677	+17.18%	+42.14%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,040.28 cr	65.380043	+21.03%	+21.93%
CIPLA	CIPLA LTD	116,452.52 cr	30.005339	+11.79%	-2.75%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	115,616.29 cr	23.056854	+17.93%	+17.85%
LUPIN	LUPIN LIMITED	113,320.96 cr	21.221472	+26.83%	+28.27%
MAXHEALTH	MAX HEALTHCARE INS LTD	107,290.40 cr	74.382732	+14.33%	-9.32%

Try these prompts

Analyze NEPHROCARE HEALTH SERV L with valuation, momentum and industry peers
Compare NEPHROPLUS with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-07-20. Not investment advice.